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Abstract 
Ketorolac tromethamine is a non-steroidal drug that has potent analgesic and 
moderate anti-inflammatory activity. A single dose of ketorolac tromethamine is 
clinically more effective than that of many drugs in the management of moderate to 
severe postoperative pain. Transdermal delivery of ketorolac tromethamine seems as a 
potential method of administration that would be non-invasive and eliminate repeated_ 
dosing regimens. Although a transdermal dosage form of ketorolac has not arrived in the 
market, permeation enhancement of ketorolac tromethamine transdermally and topically 
has been the subject of several pharmaceutical research studies. 
The objective of this study was to evaluate the possible release enhancement 
effects of several commonly used skin emollient substances on the in vitro release of 
ketorolac tromethamine from topical emulsion formulations. The O/W emulsions 
containing 1.65% ketorolac tromethamine were prepared as topical formulations. Six 
different emulsions with three different emollients; sucrose polysoyate, di-ppg-2-myreth-
10 adipate, and ppg-3-benzyl myristate at 1 and 5% levels were prepared. The release of 
ketorolac tromethamine from each emulsion was studied in vitro using static Franz 
diffusion cells. The diffusion studies were conducted across cellulose ester and silicone 
membranes. A validated HPLC assay method was used to analyze the drug 
concentration. A linear mixed-effect model was used to test the statistical significance of 
all the release rates from the six emulsions compared to the control at a significance level 
of p<0.05. The complex viscosity and the thixotropy measurements of the emulsions 
were determined by using an Advanced Rheometer 2000. 
The release experiment results show that sucrose polysoyate significantly 
increased the release rate of ketorolac tromethamine both at 1 and 5% levels across the 
silicone membrane, although it increased the release rate of the drug only at 5% ratio 
across the cellulose ester membrane. According to the rheological analysis results, 
addition of sucrose polysoyate at 5% level increased the complex viscosity and the 
thixotropy values. Di-ppg-2-myreth-10 adipate also increased the release rate of the drug 
both at 1 and 5% levels across the silicone membrane, however it had no effect on the 
release rate of the drug at 1 % and significantly decreased the release rate of the drug at 
the 5% concentration across the cellulose ester membrane. The addition of di-ppg-2-
myreth-l 0 adipate both at 1 and 5% concentrations showed a decrease in the complex 
viscosity and the thixotropy values. PPG-3- benzyl myristate increased the release rate of 
ketorolac tromethamine both at I and 5% concentrations across the cellulose ester and the 
silicone membrane. PPG-3-benzyl myristate, at 1 % level increased the complex viscosity 
and the thixotropy value however it had no effect on the viscosity, and lowered the 
thixotropy at 5% level. 
Our in vitro test results helped us understand how the skin emollients may affect 
the diffusion rate of ketorolac tromethamine out of topical formulations and as O/W 
emulsions across two different membranes. It also gave us an idea whether these 
emollient substances could be studied and evaluated further as potential permeation 
enhancers for in vivo studies. Further, this research identified the inadvertent effect that 
emollient excipients may have on the permeation of other components when used for 
their emollient effect in various skin preparations. 
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l .0 Introduction 
1.1 Emulsions in Topical Drug Delivery 
An emulsion is a thermodynamically unstable system that consist of at least two 
immiscible liquid phases, one of which is dispersed as globules in the other liquid 
phase, stabilized by the presence of an emulsifying agent (1). One of the liquid 
phases in the emulsion is fundamentally polar or aqueous, whereas the other liquid 
phase is relatively non-polar or oil. In general, there are two types of emulsion 
systems. When the aqueous phase is dispersed in the oil phase, it is referred to as a 
water-in-oil (W/O) emulsion, whereas if the oil phase is dispersed in the aqueous 
phase, the system is called oil-in-water (O/W) emulsion. The particle diameter of the 
dispersed phase is given generally in the range 0.1 to 100 µm. Dermatologic and 
cosmetic lotions and creams are O/W emulsions and are acceptable among the 
patients and physicians because they spread easily and cover the affected area (1). 
Emulsions are semi-solid preparations, which are used in pharmacy, medicine and 
cosmetics, and are for applications externally to the skin or mucous membranes. 
Mixed emulsifiers of surfactant/amphiphile type are often preferred to make topical 
O/W creams. An amphiphile is defined as either a long-chain fatty alcohol or fatty 
acid particularly for cosmetic applications, and these materials are able to stabilize 
and to give body to the emulsion system. The higher fatty alcohols with a chain 
length from C14 to C18 or fatty acids such as palmitic or stearic acid are usually 
employed. The water-soluble surfactant could be anionic such as sodium lauryl 
sulfate, cationic type such as quaternary ammonium salt of bromide or a nonionic 
1 
surfactant such as ceteth-20, which is the polyethylene glycol ether of cetyl alcohol 
(2). 
1.2 Trans-Epidermal Drug Enhancers 
1.2.1 Functions and Structure of the Skin 
The skin, the heaviest single organ of the body, physically protects the internal 
organs and restricts the passage of substances into and out of the body. The skin, 
which covers an area of 1.8 m2 for an average 70-kg human being, regulates the body 
temperature and blood pressure with its circulation and evaporation systems (2). 
Despite the complex nature of the skin structure, it is composed of three layers the 
epidermis, dermis and subcutaneous tissue. Skin appendages such as hair, as well as 
sweat and sebaceous glands are originate in the skin (Figure 1 ). The epidermis is 
composed of four individual layers, from the external surface inwards, these layers are 
called the horny layer (stratum corneum), the granular layer (stratum granulosum), the 
prickle cell layer (stratum spinosum), the basal layer (stratum germinativum). The 
cells, which are formed in the basal layer of the epidermis, differentiate as they move 
outwards, and complete their final stage of differentiation by becoming flattened, 
anucleic, keratinized, stacked vertically and constitute the outermost epidermal layer of 
the skin, stratum corneum. The stratum corneum has a key role in controlling the 
percutaneous absorption of drug molecules. The next layer the dermis is composed of 
connective tissue. This layer contains the blood vessels, nerves, lymphatic, and skin 
appendages such as sweat glands, sebaceous glands. Beneath the dermis, the 
subcutaneous tissue, which is a layer of fat, connects the flexible skin and the 
underlying structures. It serves as a thermal barrier and a mechanical cushion (2). 
2 
Blood vessel 
-Papillary 
layer 
Dermis 
-Reticular 
layer 
Figure 1. Structure of the skin (3) 
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l .2.2 Percutaneous Absorption and Penetration Enhancers 
Percutaneous absorption of a drug starts with diffusion out of its vehicle to the 
stratum comeum of the skin. The stratum comeum, which has a thickness of around 
l5-20 µm over the human body, and is made up with blocks of keratin embedded in 
extra cellular lipid, constitutes the primary permeation barrier for the drug molecule ( 4). 
This barrier presented by the stratum comeum structure is explained as "brick and 
mortar" structure, which is analogous to a wall. The comeocytes of hydrated keratin 
constitute the bricks, which is surrounded in the mortar that is multiple lipid bilayers, 
which are composed of ceramides, fatty acids, cholesterol and cholesterol esters. If this 
stratum comeum were absent, the passage of most of the small water-soluble non-
electrolytes would be a thousand times more rapidly (5). One of the solutions to 
increase the permeability of the stratum comeum has been the use of penetration 
enhancers in transdermal drug delivery. Penetration enhancers are the chemicals, 
which penetrate into skin to decrease the barrier resistance of the skin. Penetration 
enhancers promote drug flux by one or more of the mechanisms described below i.e. 
making alterations at the molecular level such as: disrupting the lipid structures of the 
stratum comeum, solvating the keratins and reducing the drug/tissue binding, 
increasing the fluidity of the lipid region in the stratum comeum, interacting with the 
proteins and enhancing drug partitioning into the skin (6). 
1.2.3 Penetration Enhancement by Hydration of Stratum Comeum 
Water has long been considered to increase the transdermal and topical delivery 
of drugs. The human stratum comeum has water content of around 15-20% of the 
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tissue dry weight depending on the humidity of the environment. This water content 
can come in equilibrium with that of the dermal layer if the skin is immersed in water, 
exposed to high humidity environments, or is occluded so that the transepidermal water 
Joss is not permitted (7). Mechanisms of action by which hydration of stratum comeum 
facilitates transdermal absorption is not clearly known, however there are several 
theories that partially explains this phenomena. One of the theories is that the free 
water in the tissue could change the solubility of the drug molecule in the stratum 
comeum, however this mechanism does not explain the hydration-enhanced delivery of 
Jipophilic molecules such as steroids. Another theory is a "pore pathway" formation in 
the stratum comeum that would enhance the drug penetration. According to the theory, 
under extensive hydration, the lacunae will expand and interconnect. The lacunar 
domain is defined as the sites of comeodesmosome degradations, which lie within the 
lipid bilayers of the stratum comeum (7). 
Based on the principle of hydration of the stratum comeum, transdermal drug 
bioavailability can be improved by hydrophobic ointments, moisturizers, occlusive 
films and transdermal patches (8). Although in general skin hydration leads to an 
increase in transdermal delivery of both hydrophilic and lipohilic molecules, there are 
some studies that show occlusion does not always lead to percutaneous absorption 
enhancement (9). 
1.3. Classic Approaches to Hydrate the Stratum Comeum 
There are three classic approaches used in the pharmaceutics, cosmetics and 
personal care area to hydrate the stratum comeum: 
(a) Using Humectants. 
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Humectants, which are used in skin preparations, are water-soluble organic 
compounds that can absorb water. Humectants hydrate the stratum corneum by 
holding water that would normally be free and result in trans-epidermal water loss. 
Under high humidity conditions, these substances are also able to pull water from the 
exterior to the skin (10). Glycerol, sorbitol, propylene glycol, butylenes glycol, 
urea, sodium lactate and sodium pyrollidone carboxylic acids are among the widely 
used humectants. 
(b) Using Occlusives. 
Occlusives are used to occlude the skin, and to reduce the transepidermal water 
loss. Non-water permeable substances are utilized in most of the moisturizer 
preparations. Mineral and vegetable oils, lanolin and silicones are the primarily used 
to occlude the skin ( 11 ). 
(c) Using Emollients. 
An emollient is a substance, which gives a smooth feel and a general sense of well 
being to the skin. An emollient will even out the lines on the surface of the skin and 
make the individual corneocytes rounded (11). The mechanism of action of 
emollients is attributed to the hydration caused by their occlusive nature/ effect. 
Because any liquid, semi-solid or a solid that has a low-melting point along with a 
cosmetic quality could be utilized as an emollient, a complete list of emollients will 
be almost impossible to list here. 
Emollient substances are mainly divided into two groups: water-soluble and oil-
soluble. The polyhdric alcohols such as glycerine, propylene glycol, sorbitol, and 
ethoxylated lipids are the water-soluble emollient substances. Glycerine and 
6 
propylene glycol are used both as a humectants and emollients between 15-30% in 
topical pharmaceutical formulations and cosmetics (12). The oil-soluble emollients 
comprise a longer list of substances that could be classified into several chemical 
groups such as hydrocarbon oils and waxes, silicone oils, vegetable oils, fats, alkyl 
esters, fatty acids and alcohols, and ethers of fatty alcohols. Hydrocarbon oils, waxes 
and silicone oils are very occlusive substances in nature. They are able to form a 
hydrocarbon barrier on the skin and are very efficient in preventing the evaporation of 
water that is supplied by the underlying tissues of the stratum comeum. The silicone 
oils such as dimethyl polysiloxanes and mixed methyl phenyl polysiloxanes are non-
polar, chemically inert, and skin protectant substances. Silicone oils are less 
occlusive than mineral oil, and by being a skin protectant they do not remove the 
sebum from the skin, and present a good barrier to chemical irritants (13). Because 
the fatty acid glycerides make the 50% of human sebum, and 5.5 to 37.5% of the skin 
surface lipids, the vegetable, animal oils and fats are included in the emulsions as 
emollient substances. Examples of vegetable oils are peanut, safflower, olive, 
avocado, corn, and castor oils. Animal oils and fats are mink oil, turtle oil, tallow and 
hydrogenated tallow (13). Alkyl esters are light, easily spreadable oily substances 
such as isopropyl myristate and isopropyl palmitate. Today, there is an ever-
increasing range of synthetic esters that have unique and multifunctional properties. 
Alkyl ester type emollients give a smooth and non-greasy film on the skin when 
applied, and alkyl esters have properties such as pigment wetting, hydroalcohol 
solubility, emulsification (13). Fatty acids such as lauric, myristic and stearic acid are 
also used as emollient substances for their slip properties and mild occlusive 
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properties. Lauryl, myristyl, cetyl, stearyl alcohols are among the examples of fatty 
alcohols; and ethoxylated lauryl, cetyl, stearyl, isostearyl are few examples for fatty 
alcohol ethers that are used as emollient substances. 
1.4. Emollients Used in this Study 
1.4.1 Sucrose Polysoyate 
Sucrose polysoyate is a mixture of esters of glycine soja (soy) acid and sucrose. 
This material is defined as a skin conditioning agent- emollient and as a surfactant-
emulsifying agent (14). Sucrose polysoyate is chemically composed of a sucrose 
backbone esterified with six to eight soybean fatty acid chains. Figure 2 shows the 
chemical structure of a sucrose backbone, which has eight hydroxyl groups that are 
available for esterification. Table 1 displays the composition of soybean oil fatty 
acids. Esterification of lipophilic fatty acids to hydrophilic sucrose moiety gives a 
structure that has lipophilic and hydrophilic surface active functionality. The number 
of mono-, di-, tri-, ... , hepta- or octaesters of fatty acid esters of sucrose in the mixture 
establish the lipophilic or hydrophilic character of the mixture. The degree of 
esterification of the sucrose backbone is the number of sucrose hydroxyl groups, 
which are esterified with the fatty acids (15). The functional properties of sucrose 
fatty acid polyesters are described by their hydrophilic-lipophilic balance (HLB) 
numbers that are controlled their degree of esterification. Sucrose esters may be 
manufactured at many different HLB values (HLB number between 5-16 would be 
accepted as high, whereas HLB number between 2-6 would be accepted as a low 
8 
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Figure 2. Structure of the sucrose backbone (16) 
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Table I. 
Composition of Soybean Oil Fatty Acids (17) 
Fatty acid Percent of total(%) 
Saturated fatty acids 
Pal mi tic (C 16:0) 11 
Stearic (Cl8:0) 4 
Unsaturated fatty acids 
Oleic (Cl8:1) 
Linoleic (Cl 8:2) 
Alpha Linolenic (Cl 8:3) 
24 
54 
7 
10 
value) depending on the fatty acid chain length and degree of substitution of the 
sucrose structure (18). According to the HLB of the sucrose esters, those that have a 
low HLB value of 3-6 will stabilize w/o emulsions, the ones that have an intermediate 
HLB number between 8-13 will stabilize o/w emulsions, and those with HLB 
numbers higher than 13 will work as a solubilizer. Sucrose polysoyate has an HLB 
number of 4.91 provided in the specification sent by the supplier. 
1.4.2 Di-PPG-2 Myreth-10 Adipate 
Di-PPG-2 Myreth-10 Adipate is 100% active alkoxylated di-ester of myristyl 
alcohol and adipic acid. This material is defined as a multifunctional emollient with 
good irritation mitigation. It solubilizes Benzophenone-3 and hair dyes. It has an 
HLB number of 4.16, and it is oil soluble and water dispersable ( 19). The addition of 
ethylene oxide and propylene oxide to an ester of myristyl alcohol and adipic acid 
gives an ethoxylated surfactant type property to this emollient. The chemical 
structure of di-PPG-2 Myreth-10 Adipate is given in the Figure 3. 
1.4.3 PPG-3 Benzyl Myristate 
PPG-3 Benzyl Myristate is the ester of propoxylated myristic acid and the benzyl 
alcohol. The chemical structure is presented in the Figure 4. This material is 
manufactured as an emollient that is superior to silicone in terms of shine and feel 
enhancement for the personal care products (20). The substance is designed so that 
the alkoxylation improves the dispersability and the feel characteristics of skin care 
formulations. The benzyl group enhances the compatibility of the substance in 
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Figure 3. Chemical Structure ofDi-PPG-2 Myreth-10 Adipate 
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Figure 4. Chemical Structure of PPG-3 Benzyl Myristate 
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products such as sunscreens and fragrances. It is oil soluble, and has an HLB number 
ofI3.49. 
l .5 Ketorolac Tromethamine 
Ketorolac tromethamine is a nonsteroidal drug that has potent analgesic and 
moderate anti-inflammatory activity. Figure 5 shows the chemical structure of 
ketorolac tromethamine. Ketorolac tromethamine is available as an oral dosage form; 
topical dosage form as an ophthalmic solution and as an injectable that is 
intramuscularly and intravenously (21). Transdermal delivery of the drug is proposed 
to be an alternative type of administration, which is considered as non-invasive and 
will reduce repeated dosing regimens (22). The benefits that are associated with the 
ketorolac tromethamine administration are listed as: adequate analgesic effect, no 
sedation, absence of respiratory depression and urinary retention, reducing the 
excitement that is seen along with the inhalational anesthesia use (23). 
1.6 In Vitro Drug Release Studies 
An experimental method to study the percutaneous absorption of a drug from a 
topical formulation may be achieved by using in vivo and in vitro techniques. In vitro 
release experiments using excised human or animal skin are morally more desirable, 
less expensive and less time consuming compared to in vivo studies. In vitro release 
experiments are valuable for screening procedures and understanding the effects of 
physicochemical parameters such as flux rates, partition coefficients, and diffusion 
14 
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Figure 5. Chemical Structure ofKetorolac Tromethamine 
15 
coefficients. One of the commonly used diffusion-cell systems is the Franz diffusion 
cell. A static Franz cell is represented in the Figure 6, which is composed of a donor 
compartment and a receptor compartment. The excised human or animal skin or an 
artificial membrane is placed between the donor and the receptor compartments. The 
o-ring is inserted to support and maintain the membrane flat throughout the 
experiment. Then the compartments are clamped. The receptor compartment is 
usually filled with phosphate buffer to mimic the body fluids, and/or a solution in 
which the drug solubility is enhanced. The topical formulation is placed on the donor 
compartment. Aliquots from receptor solution are at specified time intervals to 
determine drug flux and withdrawn solution volume is replenished to assure the sink 
conditions. The passage of the drug molecule from the donor compartment to the 
receptor fluid is quantified (24-25). 
Excised skin and artificial membranes are widely used in in-vitro for quick 
assessment of the product efficacy because of the high cost of screening large 
numbers of candidate formulations and the need to determine the toxicity levels of 
novel compounds (26). 
Cellulose ester membrane, one of the artificial membranes, is widely used in in-
vitro diffusion studies to determine the effect of vehicle or formulation variables on 
the overall drug availability. Cellulose ester membranes are manufactured from 
cellulose acetate. The material is processed and extruded into tubular membranes or 
flat sheets (27). Figure 7 displays an image of cellulose ester membrane. The 
permeation of a series of steroids through a cellulose acetate membrane was reported 
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Figure 7. Cellulose Ester Membrane (28) 
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to be dependent primarily on membrane-water partition coefficients of the steroids so 
that the least polar compound was permeated the fastest (29). Cellulose acetate and all 
dialysis membranes are examples of porous barriers. Thus the transportation of the 
solute or the drug molecule will be through the solution-filled pores. The rate of 
diffusion is determined by the probability that a molecule will enter a pore as well as 
the tortuosity of the pores. Although a cellulose acetate membrane cannot be 
considered an exact model for human skin, its mechanism of activity has been 
considered as a model of a damaged skin (30). 
Silicone sheeting which is a polymethylsiloxane membrane is another artificial 
membrane used in vitro diffusion studies. The silicone elastomer is considered as a 
partitioning-membrane system, which is mechanistically relevant membrane model 
for the skin penetration studies (30). 
1.7 Objective 
Ketorolac tromethamine is rapidly absorbed, and it reaches the maximum plasma 
concentration in 30 to 40 minutes after oral administration to healthy volunteers. The 
maximum plasma level is reached within 45 to 50 minutes if it is administrated 
intramuscularly. The systemic availability of ketorolac is reported to be 
approximately 80% after taken orally. The drug is administered to the patients who 
have moderate to severe postsurgical pain as single dose regimens, although it is 
administered 4 times daily up to 7 days to the patients, who have acute 
musculoskeletal pain (31 ). Transdermal delivery of ketorolac has been the subject of 
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phannaceutical research by many scientists due to the need for repeated dosing 
regimens. Transdermal delivery is considered as a non-invasive drug administration. 
It has been reported that when ketorolac tromethamine was included in the solvent 
mixtures of propylene glycol and linoleic acid in proportions of 7:93 and propylene 
glycol and oleic acid in proportions of 8:92 and these solvents were applied to the 
rhesus monkeys that were used as a model for human skin penetration, significantly 
high ketorolac tromethamine plasma levels were obtained after a 24-hour transdermal 
patch application (32). 
Effects of vehicles and penetration enhancers for ketorolac tromethamine were 
studied in another study revealed that pure propylene glycol monolaurate enhanced 
the penetration of ketorolac tromethamine across excised hairless mouse skin. When 
cosolvent systems were evaluated in this study, it has been concluded that a solution 
of 20 to 60 % diethylene glycol monoethyl ether either with propylene glycol 
monocaprylate or propylene glycol monolaurate could be used to enhance the skin 
permeation of ketorolac tromethamine. In addition, a vehicle that consisted of 10% 
propylene glycol in caprylic acid has been found out to increase ketorolac permeation 
(33). 
In a study with lecithin-stabilized microemulsions for topical delivery of ketorolac 
tromethamine, it has been reported that an organogel which is composed of 40% 
lecithin, and 60% isopropyl myristate that contained 0.6 % w/w of water and 6.5 
o/ow/w of ketorolac tromethamine gave the highest drug release rate in vitro through 
guinea pig skin as a human skin model (34). 
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penneation enhancement of ketorolac tromethamine has also been studied in 
healthy humans, and a mixture of isopropyl alcohol: water: isopropyl myristate 
(50:50: 1.5) has been suggested as transdermal patch composition that achieved the 
highest plasma concentration (35). 
The objective of this study was to prepare O/W emulsions of ketorolac 
tromethamine with three different skin emollient substances and study the possible 
effects of these emollients on in vitro diffusion of this drug across two artificial 
membranes. These three emollients, which are chemically either sugar esters or the 
esters of fatty alcohols and acids, are used in the cosmetic preparations because they 
improve the skin feel, softness and smoothness. Sucrose polysoyate is acknowledged 
for its moisturization improvement and its protective effect on skin barrier. PPG-3 
benzyl myristate has silicone-like feel and functionality with film-forming ability. 
Di-ppg-2 myreth 10 adipate is proposed to be a good slip enhancer. The 
moisturization and film forming abilities may lead the hydration of stratum comeum 
and thus could increase the permeation of the model drug. In our study, we are going 
to understand the possible effects of these emollients on the release of the model drug 
across artificial membranes on in vitro diffusion experiments. 
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2.o Materials 
2.1 Instrumentation 
The concentration determination of Ketorolac tromethamine was determined by 
using an HPLC (Agilent 1100 Series UV Spectrometer). It consists of a Milton Roy, 
Consta Metric III metering pump, a monitor, and a Hewlett Packard Integrator. The 
wavelength was set at 322 nm. Peak heights were automatically programmed by the 
integrator. Chromatography was achieved using a C-18 (3 .9 mm id x 300 mm) 
column. The mobile phase was prepared by mixing acetonitrile and 1.3 mM 
Phosphoric acid solution (pH= 3.02) at a ratio of 34:66. The flow rate was kept at 1.5 
mL/minute (36). The mobile phase was freshly prepared, mixed with a magnetic 
stirrer, and then filtered by 0.45 µm nylon filters (Millipore, Bedford, MA). 
An Advanced Rheometer 2000 TA (New Castle, DE) was used to measure the 
complex viscosity and the thixotropy values of the emulsions. A 6 cm acrylic cone 
(New Castle, DE) was used. 
2.2 Chemicals and Reagents 
Ketorolac Tromethamine, USP injectable grade was purchased from Medilom& 
Co. N.V. (Antwerp, Belgium). Potassium acid phosphate anhydrous, sodium 
chloride, o-phosphoric acid, and HPLC grade acetonitrile were purchased from Fisher 
Scientific (Fairlawn, New Jersey). Disodium phosphate anhydrous was purchased 
from J.T. Baker Chemical Co. Sucrose polysoyate, di-ppg-2-Myreth-10 adipate, and 
ppg-3-benzyl ether myristate were kindly supplied by Croda Inc. (Edison, New 
Jersey). Non-reinforced Silicone sheeting was purchased from Advanced Bio-
Technologies Inc. (Clearwater, Florida). Cellulose ester membrane was purchased 
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from Spectrum Lab. Inc. (Rancho Dominguez, CA). Light mineral oil was purchased 
from Mays Chemical Co. (Indianapolis, IN). Stearyl alcohol was purchased from 
Henkel Co., Carbopol ETD 2020 was purchased from Noveon Inc. (Cleveland, OH). 
Yellow beeswax, NF pastilles, were kindly supplied by Strahl&Pitsch Inc. (West 
Babylon, New York). Brij 721S and Span 60S were kindly supplied by Uniqema 
(New Castle, DE). Germaben II was kindly supplied by ISP Sutton Labs. (Chatham, 
New Jersey). Bottled distilled water was purchased from Poland Spring (Greenwich, 
CT) 
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3.o Methods 
3.1 Preparation of Emulsions 
Ketorolac tromethamine (KT) (1 .65% w/w) was weighed accurately and dissolved 
in distilled water. It was stirred with the anchor type-stirring blade to ensure that it 
was completely dissolved. Carbopol ETD 2020 (0.1 % w/w) was dispersed in the KT 
solution at an agitation of 500 RPM for 15 min. Sorbitol (5.65 % w/w) and Brij 721 S 
were added to the water phase, and it was heated to 75 °C. The oil phase, which 
consisted of mineral oil, stearyl alcohol, yellow beeswax and Span 60S, was blended 
together in a beaker and heated to 75 °C. The oil phase was added to the water phase 
at 75 °C, and stirred with an agitation of 300 RPM. 0.15 g of 10% (w/v) sodium 
hydroxide solution was added. The crude emulsion was kept stirring until it cooled to 
60 °C, and then homogenized using a Premier Mill Corp. homogenizer for 2 min at 
3000 RPM. After the homogenizing process, the emulsion was mixed slowly with a 
T-shape blade. Gerrnaben II (1.00% w/w) was added to the emulsion at 40 °C, it was 
kept slowly mixing down to 24-25 °C. All the emulsions contained the same amount 
of KT, distilled water, carbopol ETD 2020 and Gerrnaben II. Six different emulsions 
were prepared by adding three different emollients at two different levels (1 % and 
5%, w/w). The amount of Span 60S and Brij 721 S was determined by using the 
required hydrophilic lipophilic balance calculation for each emollient and levels. A 
total of I 00 g of each emulsion was prepared, and kept in glass jars at room 
temperature for one week until use. At the time the emulsions were one week old. 
The pH was adjusted to approximately 6 by adding 0.15± 0.03 g of 10% (w/v) 
sodium hydroxide solution if necessary (Table 2 and 3). 
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Table 2. 
Water Phase Compositions of the Emulsions (%w/w) 
Emulsion Brij721S 
Control 3.46 
1% Sucrose Polysoyate 3.37 
5% Sucrose Polysoyate 2.78 
1%Di-PPG-2 Myreth-10 Adipate 3.38 
5%Di-PPG-2 Myreth-10 Adipate 2.74 
1% PPG-3-Benzyl Myristate 3.48 
5% PPG-3-Benzyl Myristate 3.57 
All emulsion water phases contain the same % w: 
Water 
Sorbito/ 
Ketoro/ac Tromethamine 
Germaben II* 
Carbopol ETD2020 
%w/w 
63.45 
5.65 
1.65 
1.0 
0.1 
NaOH (10% sol.) 
0.21 
0.15 
0.22 
0.23 
0.15 
0.15 
0.24 
* Gennaben II includes the following ingredients: Propylene glycol, diazolidinyl urea, 
metyl and propyl paraben. 
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Table 3. 
Oil Phase Compositions of the Emulsions* % (w/w) 
Emulsion Miner al Oil S. Alcohol Y. Beeswax Span 60S 
Control 20.00 2.00 1.00 1.54 
1% Sucrose Polysoyate 19.24 1.84 0.92 1.63 
5% Sucrose Polysoyate 16.00 1.20 0.80 2.22 
1% Di-PPG-2 Myreth-10 Adipate 19.24 1.84 0.92 1.62 
5%Di-PPG-2 Myreth-10 Adipate 16.00 1.20 0.80 2.26 
1% PPG-3-Benzyl Myristate 19.24 1.84 0.92 1.52 
5% PPG-3-Benzyl Myristate 16.00 1.20 0.80 1.43 
* The oil phase contained the % amount of the emollient that is designated with the name 
of the emulsion. Likewise, 1 % Sucrose Polysoyate contains 1 % Sucrose Polysoyate in the 
oil phase. 
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2 Release Studies 3. 
The formulated emulsions were placed on either a cellulose ester or silicone 
membrane and the release ofketorolac tromethamine from the emulsions and through 
the membranes was determined by using a Franz static diffusion cell system. The 
Franz cell had a radius of I cm, and a volume of I 0.0 ml. The membranes were 
placed between the donor and the receiver compartments, and then the o-ring was 
placed on the rims of the receiver compartment between the donor compartment. The 
effective area for diffusion was 3.14 cm2. In each experiment, 1.5 g of emulsion 
containing the drug was placed on the membrane in the donor compartment. The 
receptor compartment was filled with I 0.0 ml of degassed isotonic phosphate buffer 
solution at pH 7.4. The temperature of the Franz cells was maintained at 32 °C by 
circulating water through the water jackets of the cells using a circulatory water bath. 
The receptor solution was stirred with a magnetic stirrer once the console, which was 
holding the cells, was turned on. I 0 ml of receptor solution was withdrawn 
completely at 0.5, 1, 2, 4, 6, 8, l 0 and 12 h. The receptor solution was replaced with 
fresh isotonic phosphate buffer solution. The withdrawn sample solutions were 
stored in glass scintillation vials, and kept in the refrigerator until the concentration 
measurement. The ketorolac tromethamine concentration in each vial was 
determined by using an HPLC. 
3.2 Preparation of Membranes 
The cellulose ester membrane was soaked in distilled water for 30 min, and was 
washed with distilled water to get rid of the preservative, sodium azide. Then, it was 
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placed in a bath of distilled water for 24 h in the refrigerator. Thirty min before the 
experiment, it was placed in fresh phosphate buffer solution. 
The silicone sheet was washed with distilled water, and received the same post 
treatment as the cellulose ester membrane. 
3.4 Release Data Analysis 
The cumulative amount of ketorolac tromethamine, which was released out of the 
emulsion and through the membrane, was plotted as a function of time. The release 
rate (µglcm2/h) of the drug was calculated from the slope of the graph. 
3.5 Analytical Assay for Ketorolac Tromethamine 
An HPLC method was used to detect the amount of ketorolac tromethamine that 
released from the formulation into the receptor medium. A C-18 column with a 3 .9 
mm i.d.x 300 mm was used to elute the drug along with mobile phase, which was 
consisted of acetonitrile and 1.3 mM phosphoric acid solution (pH= 3.02) with a 
proportion of 34:66 (v/v). The flow rate was programmed as 1.5 ml/min, and the 
injection volume was 20µ1 (36). The retention time of each chromatography was 8 
min, and the detection wavelength was set at 322 nm. 
3.6 Analytical Data Analysis and Validation Study for the Ketorolac Tromethamine 
Assay 
The concentration of ketorolac tromethamine was determined according to two 
different calibration curves, which were constructed by plotting the peak height 
,, 
obtained from the chromatography versus known drug concentrations. 
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Concentrations of 0.1, 0.25, 0.5, 1, 3 µg/ml and 5, 7, 10, 15, 20 µg/ml were prepared 
to construct the calibration curves for the silicone membrane, and cellulose ester 
membrane, respectively. For some experiments, the drug solution was diluted with 
the phosphate buffer to appropriate concentrations before analysis. 
Both of the calibration curves were found to be linear in the concentration range from 
0.1 µg/ml to 3µg/ml for the silicone membrane (Figure 8), and from 5 µg/ml to 20 
µglml for the cellulose ester membrane (Figure 9) with mean regression coefficient 
(R2) values of 0.998. 
An inter-day and intra-day analytical method validation study was performed on 
three different days by constructing the calibration curves for three different 
concentrations of KT solution in phosphate buffer. 
Each solution was injected six times, and RSD and % recovery values were 
calculated according to the FDA reviewer guidance, validation of chromatographic 
methods, published by CDER (37). The values obtained are tabulated in a table in 
Table 4 and 5. 
3.7 Statistical Analysis 
All the experiments were carried out six times. Their mean values, and the 
standard deviation values were calculated. A linear mixed-effect model was used to 
test the statistical significance of all the release rates of six emulsions compared to the 
control. It was assumed that the differences were significant at p< 0.05. The results 
of the linear mixed-effect model test are given in Table A 1 and A2, Appendix. 
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Table 4. 
Inter-day Method Validation Data for Ketorolac Trometharnine (KT) for the Cellulose 
Ester and Silicone Membrane 
KT Added KT Measured (ug/ml)* 
DAYI DAY II DAY III 
Silicone membrane concentrations 
0.50 
1.00 
3.00 
0.50±0.01 0.52±0.01 0.49±0.05 
1.00±0.03 0.98±0.03 1.01±0.01 
3.00±0.02 3.00±0.02 3.00±0.15 
Cellulose ester membrane concentrations 
7.00 
10.00 
20.00 
6.49±0.13 6.80±0.07 6.84±0.07 
10.27±0.08 10.27±0.18 10.21 ±0.07 
19.94±0.11 19.94±0.34 19.95±0.17 
Precison, 
RSD 
3.03 
1.53 
0.00 
0.39 
0.34 
0.03 
*The data represents the mean ± standard deviations of six replicates. 
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Accuracy, 
% Recovery 
100.67 
99.67 
100.00 
97.29 
102.50 
99.72 
Table 5. 
Intra-day Method Validation Data for Ketorolac Tromethamine (KT) for Cellulose Ester 
and Silicone Membranes 
KT Added KT Measured (ug/ml) * 
Measurement I Measurement II Precison, 
RSD 
Silicone membrane concentrations 
0.50 
1.00 
3.00 
0.52±0.01 
0.98±0.03 
3.00±0.02 
0.52±0.01 
1.02±0.02 
2.95±0.03 
Cellulose ester membrane concentrations 
7.00 
10.00 
20.00 
6.84±0.07 
10.21±0.07 
19.95±0.17 
6.69±0.17 
9.99±0.06 
21.38±0.75 
0 
2.83 
1.19 
1.57 
1.54 
4.56 
*The data represents the mean ± standard deviations of six replicates. 
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Accuracy, 
% Recovery 
104.0 
100.00 
99.17 
96.64 
101.00 
103.08 
Rheological Analysis of Emulsions 
3.8 
An Advanced Rheometer 2000 (TA Instruments) was used to assess the 
rheological characterization of six emulsions and the control. A 6 cm (diameter) 
acrylic truncated (32 microns) cone was used for all the rheology experiments. 
3.8.1 Complex Viscosity Measurement 
Before any testing, all the emulsions were placed in a plastic centrifuge tubes, and 
then centrifuged at 600 rpm for 5 min (38). The emulsions had been stored 
untouched overnight. For each measurement, a sample of the emulsion was placed on 
the middle of the lower plate with the help of a spatula. This treatment ensured that 
all the emulsions had the same rheological history and minimum structural 
disturbance before testing. 
The oscillatory shear method was used to assess rheological parameters such as 
G' (the dynamic storage modulus), G" (the dynamic loss modulus) and the ri* (the 
complex viscosity). 
When an emulsion sample was subjected to an oscillatory stress, the rheometer 
was able to detect the periodic strain, which was generated from the deformation 
within the sample. 
A strain sweep test was performed in order to obtain the linear viscoelastic region 
for all the emulsions. It was achieved by varying the stress applied at a given 
oscillation rate. Thus, the sweep was conducted from the 0.01 % to 100% strain range 
at a rate of 15 rad/sec. All emulsions displayed linear viscoelastic region up to the 
I% strain level. 
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A frequency sweep was also performed in the same oscillatory mode from I to 
1 OO rad/sec and 0.6% was determined as the strain level for all of the emulsions, so 
that stress would never exceed the linear viscoelastic region. 
3.8.2 Thixotropy Measurement 
A flow test method was performed to evaluate the thixotropy of all the emulsions. 
A continuous ramp with a shear rate from zero to 50 sec·' was run in order to 
construct the up curve. To obtain the down curve, a reversed shear rate from 50 to 
zero sec·' was applied in a second continuous ramp. A pause of 2 min was 
established between the up and the down curve. 
3.9 Rheological Data Analysis 
The computer automatically generated the complex viscosity values for each of 
the emulsions. The experiment was performed twice for each emulsion and the 
average of the two tests were calculated at the frequency of 1 rad/sec for all of the 
samples. 
The thixotropy value for each emulsion was calculated from the hysteresis area 
which is the area between the ascending curve and the descending curve. The 
hysteresis area was calculated by using a SAS program. The experiment was 
repeated three times, and the shear stress and the shear rates that were used to 
construct the flow chart were the averages of the three experimental results. 
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0 Results and Discussion 4. 
4.1 Results ofKetorolac Tromethamine Analytical Assay and Validation Study 
The calibration curves were found to be linear in the concentration ranges from 
0.1 µg/ml to 3 µg/ml for the silicone membrane, and from 5 µg/ml to 20 µg/ml for the 
cellulose ester membrane with mean regression coefficient (R2) values of 0.998 
(Figures 8 and 9). The mean interday percent recovery for the three concentrations 
each representing a low, medium and high concentration in the calibration range for 
the silicone membrane were 100.67, 99.67, and 100.00 %. The inter-day percent 
recovery for the three concentrations for the cellulose ester membrane were 97.29, 
102.50, and 99.72 % (Table 4). The intra-day percent recovery of these same 
concentrations were found to be 104.0, 100.0, 99 .17 % for the silicone membrane, 
and the intraday percent recovery for the cellulose ester membrane concentrations 
were found to be 96.64, 101.00, and 103.08 % (Table 5). 
4.2. Results of Release Studies 
4.2.1 Release of Ketorolac Tromethamine from Emulsions Containing Sucrose 
Polysoyate Across the Cellulose Ester and the Silicone Membranes. 
The release profiles across the cellulose ester membrane for the emulsions 
containing 1, 5 % sucrose polysoyate and the control are given in Figure 10 and Table 
6. They show that there is no lag time for the release of ketorolac tromethamine out 
of the emulsions. Analysis of the results using the linear mixed effect model 
indicates that the addition of 1 % sucrose polysoyate did not change the release rate 
significantly from that of the control. However addition of 5% sucrose polysoyate 
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Table6. 
I tive Released Amounts of Ketorolac Tromethamine Across Cellulose Ester cumua 
Membrane from Control Emulsion and the Emulsions Containing 1 and 5% Sucrose 
Polysoyate 
Control Emulsion 
TiJne (hr) 
0.5 
1 
2 
4 
6 
8 
10 
12 
Cumulative Amount (µg/cm2) 
56.52 
121.38 
250.37 
488.88 
701.24 
1004.57 
1178.93 
1270.93 
Emulsion Containing I % Sucrose Polysoyate 
Time (hr) 
0.5 
I 
2 
4 
6 
8 
IO 
12 
Cumulative Amount (µg/cm2) 
68.90 
138.60 
265.94 
496.79 
707.59 
916.15 
1108.13 
1274.90 
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STD EV 
46.30 
113.31 
209.77 
364.57 
522.69 
608.13 
721.87 
772.25 
STD EV 
62.55 
132.66 
242.34 
433.55 
570.81 
731.71 
880.20 
1008.96 
Table 6 Contd. 
Emulsion Containing 5% Sucrose Polysoyate 
Time (hr) 
0.5 
2 
3 
4 
6 
8 
IO 
12 
Cumulative Amount (µg/cm2) 
156.55 
637.71 
962.93 
1241.18 
1768.19 
2255.91 
2678.27 
3143.09 
39 
STD EV 
50.07 
134.66 
178.12 
235.17 
280.44 
341.68 
374.04 
442.16 
increased the release rate significantly (256.09 µg/cm2/hr) compared to the release of 
the 1 % (105.54 µg/cm2/hr) and the control (111.19 µg/cm2/hr). 
The release profile of drug from the emulsions containing 1 and 5% sucrose 
polysoyate and the control across the silicone membrane is given in Figure 11 . 
Figure 11 and Table 7 show that as was seen with the cellulose ester membrane, there 
is no lag time in the release of ketorolac tromethamine out of the emulsions and 
across the silicone membranes. Analysis of the results using the linear mixed effect 
model indicates that addition of either the 1 and 5% sucrose polysoyate increased the 
release rate of the ketorolac tromethamine significantly (3.50 µg/cm2/hr and 3.44 
µglcm2/hr, respectively) compared to the control (0.33 µg/cm2/hr). In contrast to the 
cellulose ester membrane, the increase from emulsion containing sucrose polysoyate 
from 1 to 5% in the silicone membrane systems did not show a significant difference 
in diffusion rate across the membrane as a function of emollient concentration. 
However, the rate of release of both concentrations of sucrose polysoyate was 
significantly different from the control. 
The release rates of ketorolac tromethamine from the control emulsion across the 
cellulose ester and the silicone membrane were found out 111.19 µg/cm2 /hr, and 0.33 
µg/cm2/hr, respectively. The overall difference in the observed release rates of drug 
from the control emulsions across the two different membranes may be attributed to 
the difference in the chemical natures of these membranes. The cellulose ester 
membrane is a hydrophilic membrane, whereas the silicone is a lipohilic membrane. 
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Figure l l. Release Profile of Ketorolac Tromethamine From Emulsions Containing I and 
5 % Sucrose Polysoyate Across Silicone Membrane 
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Table 7. 
Cumulative Released Amounts of Ketoro/ac Tromethamine Across Silicone Membrane 
from Control Emulsion and Emulsions Containing 1 and 5% Sucrose Polysoyate 
Control Emulsion 
Time (hr) 
0.5 
1 
2 
4 
6 
8 
10 
12 
Cumulative Amount {µg/cm2) 
0.24 
0.42 
0.62 
1.22 
1.88 
2.57 
3.30 
4.15 
Emulsion Containing 1 % Sucrose Polysoyate 
Time (hr) 
0.5 
1 
2 
4 
6 
8 
10 
12 
Cumulative Amount (µg/cm2) 
3.09 
5.25 
9.01 
15.85 
22.74 
29.56 
36.15 
44.10 
42 
STD EV 
0.18 
0.37 
0.44 
0.50 
0.62 
0.72 
0.86 
0.87 
STD EV 
2.50 
3.67 
4.48 
5.06 
5.61 
5.94 
6.44 
6.77 
Table 7 Contd. 
Emulsion Containing 5% Sucrose Polysoyate 
Time (hr) 
0.5 
1 
2 
4 
6 
8 
to 
12 
Cumulative Amount (µ.g/cm2) 
3.53 
5.51 
8.85 
15.61 
22.56 
29.42 
36.35 
43.26 
43 
STD EV 
3.49 
3.68 
3.91 
4.34 
4.69 
4.86 
5.22 
5.52 
It is well known that according to the pH-partition hypothesis, only un-ionized 
molecules pass through lipid membranes (39). The pH of the emulsions are 
approximately 6.00. At this pH since the pKa of ketorolac tromethamine is 3.5, the 
ratio of the ionized drug species to the un-ionized species is 316 to 1. Since the ratio 
of the un-ionized drug species is significantly lower than the ionized species, the 
release rate across the silicone membrane would be expected to be lower as compared 
to the release rate across the hydrophilic membrane. 
Addition of sucrose polysoyate to the emulsion at the 5% concentration level 
significantly increases the in vitro diffusion rate of the drug across the cellulose ester 
membrane. It has been reported in the literature that some sucrose mono-esters, 
which have a high HLB, increase the absorption of various drugs in both in vivo and 
in vitro permeation studies ( 40-42). The sucrose moiety in the sucrose polysoyate 
structure also may increase the solubility of the drug, and thus we observed a higher 
drug flux at this concentration. 
We observe that the release rate of the drug for the emulsions containing 1 and 
5% sucrose polysoyate across the silicone membrane are almost the same, and 
significantly higher compared to the release rate of the drug from the control 
emulsion. The reason that we might not be able to see a significant difference in 
diffusion rates across the silicone membranes as a function of emollient concentration 
may be that at 5%, the drug could become more water-soluble, and thus this may not 
show as a big difference in the diffusion rate of the drug across a lipophilic 
membrane. With regard to in vivo diffusion, it has been proposed that sucrose fatty 
acid esters enhance drug transport by the interaction/insertion of the fatty acid chain 
44 
Portions between the lipophilic tails of the stratum comeum bilayer lipids, thus giving 
space for the sucrose ring to interact with the polar head groups of the lipids (43). 
4.2.2 Release of Ketorolac Tromethamine from Emulsions Containing Di-PPG-2-
Myreth-1 O Adipate Across the Cellulose Ester and the Silicone Membranes. 
Tue release profile of the emulsions containing 1 and 5 % di-ppg-2-myreth-10 
adipate versus the control across the cellulose ester membrane is given in Figure 12. 
According to the evaluation using the linear mixed-effect model, the emulsion 
containing 5 % of the di-ppg-2-myreth-10 adipate emollient significantly decreased 
the release rate of the ketorolac tromethamine (14.5 µg/cm2/hr) as compared to the 
control (111.19 µg/cm2 /hr). The release rate of the emulsion containing 1 % di-ppg-2-
myreth-10 adipate showed essentially the same rate as the control with neither a 
significant increase or decrease. Figure 12 and Table 8 show that there is no lag time 
in the release of ketorolac tromethamine out of the emulsions. 
The release profiles of the emulsions containing 1 and 5% di-ppg-2-myreth-10 
adipate and the control across the silicone membrane are given in Figure 13. 
According to analysis using the linear mixed-effect model, when using silicone 
membranes, the emulsions containing 1 and 5 % di-ppg-2-myreth-l 0 adipate show a 
significant increase in the release rate of the ketorolac tromethamine, 3.09 µg/cm2/hr 
and 2.19 µg/cm2/hr, respectively as compared to the control (0.33 µg/cm2/hr). Figure 
13 and Table 9 show no lag time in the release of ketorolac tromethamine out of the 
emulsions. 
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Table 8. 
Cumulative Released Amounts of Ketorolac Tromethamine Across Cellulose Ester 
]Jembranefrom Emulsions Containing 1 and 5 % Di-PPG-2 Myreth-10 Adipate 
Emulsion Containing 1% Di-PPG-2 Myreth-10 Adipate 
Tbne (hr) 
0.5 
1 
2 
4 
6 
8 
JO 
12 
Cumulative Amount (µ.g/cm2) 
47.75 
110.73 
226.65 
418.80 
601.25 
772.99 
953.49 
1115.22 
STD EV 
47.28 
94.10 
180.68 
313.51 
407.14 
497.62 
578.03 
637.02 
Emulsion Containing 5% Di-PPG-2 Myreth-10 Adipate 
Time (hr) 
0.5 
l 
2 
4 
6 
8 
10 
12 
Cumulative Amount (µ.g/cm2) 
3.88 
9.56 
23.96 
56.36 
87.07 
116.05 
142.55 
166.80 
47 
STD EV 
5.03 
11 .69 
27.27 
61.97 
95.14 
124.63 
150.36 
173.83 
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Figure 13. Release Profile of Ketorolac Tromethamine From Emulsions Containing 1 
and 5 % Di-PPG-2-Myreth-10 Adipate Across Silicone membrane 
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Table 9. 
Cumulative Released Amounts of Ketorolac Tromethamine Across Silicone Membrane 
Jrom Emulsions Containing 1 and 5 % Di-PPG-2 Myreth-10 Adipate 
Emulsion Containing 1% Di-PPG-2 Myreth-10 Adipate 
Time (hr) 
0.5 
l 
2 
4 
6 
8 
10 
12 
Cumulative Amount (µg/cm2) 
1.30 
2.88 
6.05 
12.10 
18.30 
24.40 
30.69 
36.86 
STD EV 
0.42 
1.03 
1.66 
1.93 
2.38 
2.91 
3.18 
3.52 
Emulsion Containing 5% Di-PPG-2 Myreth-10 Adipate 
Time (hr) 
0.5 
l 
2 
4 
6 
8 
10 
12 
Cumulative Amount (µg/cm2) 
0.53 
1.46 
3.49 
7.71 
12.15 
16.73 
21.16 
25.60 
49 
STD EV 
0.06 
0.25 
0.45 
0.80 
1.03 
1.31 
1.56 
1.94 
We observe that neither the emulsion containing 1 % di-ppg-2-myreth-10 adipate 
emollient nor the emulsion containing 5% di-ppg-2-myreth-10 adipate emollient 
increased the release rate of ketorolac tromethamine across the cellulose ester 
membrane. We might explain this observation by looking at the chemical structure of 
the di-ppg-2-myreth-l 0 adipate. Di-ppg-2-myreth-l 0 adipate is an emollient with 
structural components such as ethylene oxide and propylene oxide that are similar to 
non-ionic surfactant compounds. It has been stated that unlike the ionic surfactants, 
micelles are formed by long chain polyoxyethylene non-ionic surfactants where the 
hydrophilic moiety is large enough to have a place for the solute (44). In our study, 
addition of 5 % of this emollient may have exceeded its critical micelle concentration 
so that the drug molecules may be entrapped by the emollient. Thus, we are 
observing a significant decrease in the release rate of the drug at this concentration 
across the cellulose ester membrane. 
In contrast to what we observed with the cellulose ester membrane systems, we 
found out that both the emulsions containing 1 and 5 % di-ppg-2-myreth-10 adipate 
increased the release rate of ketorolac tromethamine across the silicone membranes. 
However again at the 5% concentration level we saw a slight decrease in the release 
rate. This behavior may be explained that when the drug molecule interacts with this 
bulky emollient-with the lowest HLB number- the drug molecule is entrapped by it, 
and thus becomes more lipohilic. That is why we observe an increase in the release 
rates of the both of the emulsions across the silicone membrane. In accordance with 
the expectation of micelle formation at the 5% concentration level, the drug 
molecules may have become even more lipophilic so that the drug molecules could 
50 
not pass through the lipophilic membrane easily at 5% concentration compared to that 
of at 1 %. 
4.2.3 Release of Ketorolac Tromethamine from Emulsions Containing PPG-3-Benzyl 
Myristate Across the Cellulose Ester and the Silicone Membrane. 
The release profile of the emulsions containing 1 and 5% ppg-3-benzyl myristate 
and the control across the cellulose ester membrane is given in Figure 14. Addition 
of 1 and 5% ppg-3-benzyl myristate to the emulsion increase the release rate of the 
drug, 200.64 µg/cm2/hr and 190.73 µg/cm2/hr, respectively as compared to 111.19 
µg/cm2/hr seen for the control. Both of the emulsion formulations containing 
emollients release drug at a significantly higher rate as compared to the control. 
Figure 14 and Table I 0 show that there is no lag time in the release of ketorolac 
tromethamine out of the emulsions across the cellulose ester membrane. 
The release profile of the emulsions containing 1 and 5% ppg-3-benzyl myristate 
and the control across the silicone membrane is given in Figure 15. Both of the 
emulsions show significantly higher release rates, 1.97 µg/cm2/hr and 3.69 µg/cm2/hr 
compared to the control with a release rate of 0.33 µg/cm2/hr. The release pattern of 
the ketorolac tromethamine across the silicone membrane from emulsions containing 
1 and 5% ppg-3-benzyl myristate is similar to the release pattern that we observed 
across the cellulose ester membrane. Figure 15 and Table 11 show that there is no lag 
time in the release of ketorolac tromethamine out of the emulsions across the silicone 
membrane. 
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Figure 14. Release Profile of Ketorolac Tromethamine From Emulsions Containing 1 and 
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Table 10. 
eumulative Released Amounts of Ketorolac Tromethamine Across Cellulose Ester 
Membrane from Emulsions Containing 1 and 5 % PPG-3 Benzyl Myristate 
Emulsion Containing 1 % PPG-3 Benzyl Myristate 
Time (hr) 
0.5 
1 
2 
4 
6 
8 
10 
12 
Cumulative Amount (µ.g/cm2) 
159.19 
311.82 
606.62 
1115.94 
1522.65 
1898.69 
2194.96 
2430.22 
Emulsion Containing 5% PPG-3 Benzyl Myristate 
Time (hr) 
0.5 
1 
2 
4 
6 
8 
10 
12 
Cumulative Amount (µ.g/cm2) 
149.26 
289.31 
530.89 
955.14 
1343.46 
1694.95 
2032.38 
2346.37 
53 
STD EV 
41.36 
72.64 
120.08 
173.52 
210.84 
243.97 
277.09 
293.88 
STD EV 
105.28 
200.63 
363.05 
597.37 
814.64 
1001.84 
1170.76 
1334.88 
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5 % PPG-3-Benzyl Myristate Across Silicone Membrane 
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Table 11. 
Cumulative Released Amounts Cumulative Release of Ketorolac Tromethamine Across 
Silicone Membrane from Emulsions Containing 1 and 5 % PPG-3 Benzyl Myristate 
Emulsion Containing 1 % PPG-3 Benzyl Myristate 
Time (hr) 
0.5 
1 
2 
4 
6 
8 
IO 
12 
Cumulative Amount (µg/cm2) 
0.96 
1.85 
3.72 
7.47 
11.46 
15.57 
19.51 
23.58 
Emulsion Containing 5% PPG-3 Benzyl Myristate 
Time (hr) 
0.5 
1 
2 
4 
6 
8 
IO 
12 
Cumulative Amount (µg/cm2) 
2.62 
4.65 
8.17 
15.47 
22.77 
30.08 
37.70 
45.31 
55 
STD EV 
0.49 
0.60 
0.73 
0.85 
0.93 
0.99 
1.15 
1.26 
STD EV 
2.80 
3.76 
4.05 
3.92 
3.91 
3.66 
3.61 
3.70 
It has been reported that ppg-3-benzyl myristate mcreases the solubility of 
benzophenone-3 ( 45). Thus, ppg-3-benzyl myristate may increase the solubility of 
the drug in the emulsion, and therefore we observed significantly higher drug release 
rates at both 1 and 5% concentrations across both of the membranes systems. 
4.3 Results of Rheological Measurements 
4.3.1 Complex Viscosity Measurement 
Most semisolids are such systems that exhibit both solid and liquid behaviors. 
Tuey are described as viscoelastic bodies that will demonstrate simultaneous viscous 
and elastic properties. Dynamic oscillatory methods, which do not change the 
original material structure while applying shear to the material, are preferred to study 
the rheological properties of emulsions. In this study, a strain sweep test was 
performed in order to find out the linear viscoelastic region of each emulsion. This 
region indicates the critical stress point where the elasticity ends and viscous 
properties dominate. 
All the emulsions exhibited viscoelastic behaviour from 0.60 to 1 % strain, except 
the emulsion containing 5% sucrose polysoyate that showed viscoelastic behaviour up 
to 2% strain as shown in Figures 16-18. All emulsions were viscoelastic when the 
frequency sweep test was performed. 0.60% strain was used as the strain level for the 
complex viscosity measurements. The frequency sweep was performed in the 
oscillatory range from 1 to 100 rad/sec. The complex viscosity values are tabulated 
in Table 12. 
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Table 12. 
Complex Viscosity Values of the Emulsions 
Complex Viscosity* (Pa.s) STD EV 
Control 406.5 3.75 
1% Sucrose Polysoyate 405.6 16.62 
5% Sucrose Polysoyate 471 .2 19.52 
1% Di-PPG-2-Myreth-10 Adipate 375.3 3.32 
5% Di-PPG-2-Myreth-10 Adipate 253.7 15.77 
1% PPG-3-Benzyl Myristate 434.71 38.25 
5% PPG-3-Benzyl Myristate 410.2 5.66 
(*) The values are an average of duplicated test runs, and the data were obtained at 1 
rad/sec frequency and 0.6% strain level for all the emulsions. 
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The emulsions containing 5% sucrose polysoyate has the highest complex 
viscosity (471±19.52 Pa.s) as compared to the control (406.5±3.75 Pa.s). Addition of 
1 % sucrose polysoyate does not increase the complex viscosity as compared to the 
control. 
Addition of 1 % di-ppg-2-myreth-10 adipate to the emulsion decreases the 
complex viscosity to 375.3±3.32 Pa.s, addition of 5% di-ppg-2-myreth-10 adipate 
decreases the complex viscosity still further to 253.7±15.77 Pa.s. 
For the ppg-3-benzyl myristate, the emulsion containing 1 % ppg-3-benzyl 
myristate increases the complex viscosity to 434.71±38.25 Pa.s, however addition of 
5% ppg-3-benzyl myristate does not increase the viscosity as much as 1 % that has a 
complex viscosity of 410.2±5.66 Pa.s. 
4.3.2 Thixotropy Measurement 
Assessment of thixotropic behaviour of an emulsion system is important because 
all the emulsions will encounter a wide variety of stress starting from their 
manufacture until they are dispensed and applied on the skin. Although a certain 
level of shear thinning property is desirable to dispense the product easily, it is also 
important for the rest of the product to come back to its initial structure. 
Thixotropy is one of the most important characteristics of a topical product. It is 
defined as the decrease in viscosity of a semisolid under stress, and its gradual 
structure recovery when the stress is removed ( 46). All emulsions showed a certain 
degree of thixotropic break down when they were sheared. The hysteresis area, 
which is the area between the up and down curve, gives an estimation of the energy 
61 
required to break down the structure of the emulsion system. Thus a lower thixotropy 
value would indicate that the emulsion requires a lower amount of energy to break 
down its structure and recover compared to the one that has a higher thixotropy value. 
The thixotropy values for the emulsions are given in Table 13. According to Table 
13, the emulsion containing 1 % sucrose polysoyate has a slightly lower thixotropy 
value (690.83 Pa.s-1) compared to the control (716.62 Pa.s-1). The emulsion 
containing 5% sucrose polysoyate has a thixotropy value of 914.54 Pa§1, which is 
significantly higher than either the 1 % or the control. This finding is in line with their 
measured complex viscosities. The emulsion containing 5% sucrose polysoyate has 
the highest viscosity, thus would require the highest energy to break its structure. 
The thixotropy values for the emulsions containing 1 and 5 % di-ppg-2-myreth- l 0 
adipate are 658.57 and 595.11 Pa§1, respectively. This indicates that addition of di-
ppg-2-myreth-10 leads to lower thixotropy values compared to the control emulsion. 
This finding is also in accordance with the complex viscosity values in which we 
have observed that addition of di-ppg-2-myreth- l 0 adipate decreased the viscosity of 
the emulsion system, and decreased the thixotropic break down energy. 
As Table 13 displays, the thixotropic break down is higher for the emulsion 
containing 1 % ppg-3-benzyl myristate with a value of 908.61 Pa.s-1 compared to the 
emulsion containing 5% ppg-3-benzyl myristate that has a thixotropy value of 524.50 
Pa. s-' . This is also in accordance with the findings of complex viscosities of these 
two emulsions. Addition of ppg-3-benzyl myristate more than 1 % to the emulsion 
did not increase more neither its viscosity nor its thixotropic break down compared to 
the control. 
62 
It 
I 
Table 13. 
fhi:xotropy Values of the Emulsions 
Control 
1% Sucrose Polysoyate 
5% Sucrose Polysoyate 
1%Di-PPG-2-Myreth-JO Adipate 
5% Di-PPG-2-Myreth-10 Adipate 
1% PPG-3-Benzyl Myristate 
5% PPG-3-Benzyl Myristate 
Thixotropy* (Pa.s-1) 
716.62 
690.83 
914.54 
658.57 
595.11 
908.61 
524.50 
(*) Thixotropy values are calculated hysteresis area on the flow charts of the emulsions. 
The flow chart data were obtained as the average of three experiments. 
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The flow charts that were obtained by plotting shear rate versus shear stress are 
given in Figures 19-25. The data that show the average of three flow tests for shear 
stress versus shear rate values for all the emulsions and the control are given in 
Appendix A3. 
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S.0 conclusions 
Ketorolac tromethamine is a better alternative analgesic and anti-inflammatory 
drug compared to drugs such as aspirin, indomethacin, and naproxen. Transdermal 
delivery of ketorolac tromethamine seems to be a potential method of administration 
that will be non-invasive and eliminate repeated dosing regimen. It has been reported 
that the bioavailability of an 85 mg ketorolac tromethamine, when administered 
transdermally in rheusus monkeys, is 35%. Thus, to increase the systemic delivery of 
ketorolac tromethamine use of penetration enhancers would be of great interest in this 
research area. In this study, we have examined the effects of three emollient 
substances- sucrose polysoyate, di-ppg-2-myreth-10 adipate and ppg-3-benzyl 
myristate as o/w emulsions- on in vitro diffusion of ketorolac tromethamine across 
artificial skin membranes. 
Addition of 5% sucrose polysoyate significantly increased the ketorolac 
tromethamine in vitro diffusion across the cellulose ester membrane. We have seen a 
different diffusion pattern across the silicone membrane such that both emulsions 
containing 1 and 5% sucrose polysoyate increased the diffusion rate of the drug. 
Neither the emulsion containing 1 % di-ppg-2-myreth-10 adipate, nor the emulsion 
containing 5% di-ppg-2-myreth-10 adipate increased the release rate of ketorolac 
tromethamine across the cellulose ester membrane. Furthermore, the emulsion 
containing 5% di-ppg-2-myreth-10 adipate significantly decreased the release rate of 
the drug across the cellulose ester membrane. We have not observed this release 
pattern across the silicone membrane systems with this emollient. We observed that 
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both emulsions containing I and 5% di-ppg-2-myreth-l 0 adipate increased the release 
rate of the drug significantly across the silicone membrane. 
The emulsions containing I and 5% ppg-3-benzyl myristate were able to 
significantly increase the release rate of ketorolac tromethamine across the cellulose 
ester and the silicone membranes. 
Although in vitro studies do not replace with in vivo studies, they are vital 
because these studies add appreciably to the development and evaluation of new 
dosage forms and help in understanding underlying principles controlling absorption 
(47). In our study, these in vitro test results gave us an idea whether these emollient 
substances could be utilized as potential permeation enhancer substances. Although 
this needs to be further assessed with the in vivo studies, we can conclude that all of 
the emollient substances namely, sucrose polysoyate, di-ppg-2-myreth-l 0 adipate and 
ppg-3-benzyl myristate increased the release rate of ketorolac tromethamine 
significantly through the silicone membrane. Except di-ppg-2-myreth-10 adipate, 
which decreased or had no effect on release rate of ketorolac tromethamine across the 
cellulose ester membrane, the other two emollients sucrose polysoyate and ppg-3-
benzyl myristate were able to increase the release rate of the drug across cellulose 
ester membrane. Further, this research identified the inadvertent effect that emollient 
excipients may have on the permeation of other components when used for their 
emollient effects in various skin preparations. 
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Appendix 
Table Al. 
Table representing the results of the linear-mixed effect model test for the differences of 
release rates of the emulsions across the cellulose ester membrane 
Effect Groip_ Estimate StdErr DF tValue Probt 
lnterce_g_t 29.40411 5896.846 314 0.004986 0.996025 
Grou_g_ A1 18.86651 7984.367 314 0.002363 0.998116 
Grou_g_ A5 125.4184 7984.37 314 0.015708 0.987477 
Grou_g_ 81 -0.38182 7984.367 314 -4.8E-05 0.999962 
Grou_g_ 85 -32.4676 7984.367 314 -0.00407 0.996758 
Grou_g_ C1 159.6486 7984.367 314 0.019995 0.98406 
GrouR C5 98.92669 7984.367 314 0.01239 0.990122 
GrouR Re 0 
TIME 111.1863 27.32632 33.9968 4.068836 0.000266 
TIME*Gro~ A1 -5.64999 37.00001 33.9968 -0.1527 0.879536 
TIME*Grou~ A5 142.847 37.01195 34.04068 3.859484 0.000483 
TIME*Grou_E>_ 81 -18.8943 37.00001 33.9968 -0.51066 0.612893 
TIME*Grou_E>_ 85 -96.6868 37.00001 33.9968 -2.61316 0.013266 
TIME*Grou_E>_ C1 89.44959 37.00001 33.9968 2.417556 0.021136 
TIME*Grou_g_ C5 79.45004 37.00001 33.9968 2.147298 0.038987 
TIME*Grou_g_ Re 0 
Al: emulsion containing 1 % sucrose polysoyate, A5: emulsion containing 5% sucrose 
polysoyate, Bl: emulsion containing 1% di-ppg-2-myreth-10 adipate, 85: emulsion 
containing 5% di-ppg-2-myreth- l 0 adipate, Cl: emulsion containing 1 % ppg-3-benzyl 
myristate, C5: emulsion containing 5% ppg-3-benzyl myristate, Re: Control 
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Table A2. 
Table representing the results of the linear-mixed effect model test for the differences of 
release rates of the emulsions across silicone membrane 
Effect Group Estimate Std Err OF tValue Probt 
lnterce_.E! -0.01638 0.919739 33.00604 -0.01781 0.985894 
Grou_Q_ A1 2.000422 1.300707 33.00604 1.53795 0.133594 
Grou_Q_ A5 1.93819 1.300707 33.00604 1.490105 0.145692 
Grol!Q_ 81 -0.19652 1.300707 33.00604 -0.15109 0.880826 
Grou_Q_ 85 -0.78727 1.300773 33.01277 -0.60523 0.549165 
Grou_Q_ C1 -0.18241 1.300707 33.00604 -0.14024 0.889321 
Grou_Q_ C5 0.784718 1.454234 33.00604 0.539609 0.593089 
Grou_Q_ Re 0 
TIME 0.333906 0.09101 33.00411 3.668888 0.000852 
Tl M E*Grou_Q_ A1 3.066142 0.128708 33.00411 23.82252 2.29E-22 
TIME*Grou_Q_ A5 3.108281 0.128708 33.00411 24.14991 1.49E-22 
TIME*Grou_Q_ 81 2.752897 0.128708 33.00411 21 .38874 6.49E-21 
TIME*Grou_Q_ 85 1.855545 0.128783 33.08035 14.4083 8.2E-16 
TIME*Grou_Q_ C1 1.636795 0.128708 33.00411 12.71714 2.86E-14 
TIME*Grou_Q_ C5 3.35859 0.1439 33.00411 23.33981 4.33E-22 
TIME*Grou_Q_ Re 0 
Al: emulsion containing 1 % sucrose polysoyate, AS: emulsion containing S% sucrose 
polysoyate, Bl: emulsion containing 1% di-ppg-2-myreth-10 adipate, BS: emulsion 
containing S% di-ppg-2-myreth-l 0 adipate, Cl: emulsion containing 1 % ppg-3-benzyl 
myristate, CS: emulsion containing S% ppg-3-benzyl myristate, Re: Control 
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Table A3. 
Shear Stress versus Shear Rate Data for the Emulsions 
CONTROL 
UP CURVE 
Shear Stress ff al_ 
23.97 
30.14 
35.59 
39.60 
42.84 
44.72 
45.92 
46.65 
47.19 
47.63 
48.34 
49.43 
50.70 
51.68 
52.63 
53.02 
52.64 
52.42 
52.34 
52.99 
Shear Rate 1_1/secl_ 
2.1 3 
4.52 
7.06 
9.44 
12.11 
14.50 
17.04 
19.41 
22.08 
24.50 
27.01 
29.40 
32.07 
34.47 
37.03 
39.42 
42.04 
44.44 
47.01 
49.40 
DOWN CURVE 
Shear Stress jf'al_ 
3.64 
9.57 
14.35 
17.78 
20.57 
22.86 
25.11 
27.15 
29.02 
30.77 
32.70 
34.72 
36.61 
38.40 
40.27 
42.41 
44.44 
46.57 
49.83 
54.02 
Emulsion Containing 1% Sucrose Polysoyate 
UP CURVE DOWN CURVE 
Shear Stress ffaj_ Shear Rate jJ/secl Shear Stress jf'aj_ 
22.99 2.08 3.44 
29.71 4.47 9.57 
35.35 7.13 13.98 
38.78 9.54 17.01 
40.97 12.05 19.33 
42.37 14.45 21.46 
43.53 17.13 23.41 
44.31 19.51 25.11 
44.99 21 .98 26.70 
45.62 24.45 28.30 
45.94 27.12 29.99 
46.17 29.51 31.72 
46.55 32.03 33.52 
47.22 34.46 35.20 
47.65 37.10 36.93 
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Shear Rate 1_1/secl 
0.50 
2.89 
5.42 
7.94 
10.48 
12.85 
15.41 
17.96 
20.48 
22.87 
25.37 
27.93 
30.42 
32.86 
35.34 
37.93 
40.48 
42.85 
45.35 
47.90 
Shear Rate 1_1/secl 
0.41 
2.94 
5.47 
7.99 
10.36 
12.91 
15.44 
17.86 
20.39 
22.91 
25.41 
27.84 
30.37 
32.86 
35.42 
47.59 39.51 38.68 37.83 
47.50 41 .99 40.35 40.32 
47.28 44.41 42.35 42.86 
47.27 47.12 45.52 45.44 
47.72 49.45 49.54 47.91 
Emulsion Containing 5% Sucrose Polysoyate 
UP CURVE DOWN CURVE 
Shear Stress J!'<Q Shear Rate .1_1/secl Shear Stress J!'al Shear Rate {1/secl 
30.61 2.00 3.91 0.55 
36.81 4.53 9.04 2.94 
42.16 7.06 13.45 5.32 
45.88 9.59 17.42 7.98 
48.35 11 .98 20.38 10.54 
49.85 14.50 22.59 12.91 
51.03 17.01 24.57 15.31 
51 .87 19.56 26.72 18.13 
52.06 21 .96 28.42 20.51 
52.03 24.49 30.07 22.91 
51 .67 27.01 31 .59 25.32 
51 .61 29.59 33.36 28.09 
51 .38 31 .93 34.84 30.49 
51 .83 34.49 36.18 32.93 
52.46 37.04 37.27 35.30 
51 .98 39.57 39.07 37.92 
50.93 41.97 41 .22 40.46 
50.00 44.51 43.75 42.90 
48.96 46.91 46.69 45.30 
48.96 49.51 51 .76 47.95 
Emulsion Containing 1% di-ppg-2-myreth-10 adipate 
UP CURVE DOWN CURVE 
Shear Stress J!'<Q Shear Rate JJ!secl Shear Stress J!'al Shear Rate .1_1/secl 
20.15 2.01 4.24 0.58 
27.39 4.54 11 .85 2.97 
30.71 7.07 15.41 5.36 
33.09 9.58 17.94 7.88 
35.22 11 .98 20.16 10.54 
37.38 14.51 21 .98 12.95 
39.54 17.06 23.68 15.35 
41 .55 19.58 25.42 17.89 
43.25 21.96 27.18 20.53 
44.78 24.51 28.82 22.94 
46.14 27.06 30.46 25.34 
47.30 29.55 32.22 27.83 
48.45 31 .94 34.05 30.51 
49.66 34.50 35.72 32.91 
50.63 37.05 37.46 35.31 
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Ill 
51 .30 39.55 39.29 37.84 
51 .84 41.95 41 .25 40.56 
52.06 44.46 43.08 42.93 
52.30 47.02 44.99 45.35 
52.55 49.51 47.25 47.88 
Emulsion Containing 5% di-ppg-2-myreth-10 adipate 
UP CURVE DOWN CURVE 
Shear Stress J!'al Shear Rate {1/se<& Shear Stress 1!'<& Shear Rate JJ!secj 
32.74 2.03 4.33 0.42 
33.32 4.57 10.29 2.95 
33.03 7.10 12.52 5.34 
33.16 9.63 14.22 7.88 
33.33 12.01 15.64 10.41 
33.57 14.55 16.90 12.93 
33.74 17.07 18.10 15.34 
33.83 19.45 19.23 17.97 
33.97 21.99 20.29 20.39 
34.14 24.53 21 .36 22.92 
34.32 26.92 22.39 25.44 
34.65 29.60 23.42 27.81 
34.83 32.01 24.61 30.40 
34.81 34.55 25.78 32.93 
34.83 37.06 26.78 35.34 
34.80 39.43 28.09 38.00 
34.73 41.98 29.42 40.49 
34.79 44.51 30.47 42.91 
34.85 46.99 31.82 45.26 
34.76 49.60 33.87 47.97 
Emulsion Containing 1% ppg-3-benzyl myristate 
UP CURVE DOWN CURVE 
Shear Stress 1!'<& Shear Rate {1/secl Shear Stress J!'a)_ Shear Rate {1/sec)_ 
27.72 1.98 3.81 0.37 
35.35 4.52 10.98 3.03 
41.38 7.17 15.64 5.42 
46.30 9.57 19.24 7.95 
49.49 11 .96 22.05 10.34 
51.55 14.49 24.76 13.02 
53.05 17.03 26.95 15.41 
54.22 19.57 29.12 17.91 
55.12 21.94 31 .18 20.32 
56.44 24.50 33.41 23.01 
57.14 27.00 35.23 25.41 
57.71 29.54 37.13 27.89 
57.80 31.95 39.04 30.31 
57.62 34.49 41.46 33.02 
85 I. 
57.54 37.02 43.53 35.37 
57.59 39.51 45.63 37.93 
57.79 41.93 47.90 40.29 
57.93 44.47 50.75 42.98 
57.47 47.01 53.99 45.38 
57.22 49.45 58.81 47.90 
Emulsion Containing 5% ppg-3-benzyl myristate 
UP CURVE DOWN CURVE 
Shear Stress 1!'<& Shear Rate JJ!secl Shear Stress 1!'<& Shear Rate JJ!secl 
17.42 2.09 2.65 0.40 
21.29 4.48 7.50 3.06 
23.23 6.87 9.66 5.46 
25.43 9.66 11.32 7.86 
26.96 12.06 12.77 10.26 
28.35 14.47 14.28 13.05 
29.39 16.87 15.50 15.45 
30.32 19.63 16.70 17.86 
31.04 22.07 17.84 20.24 
31.63 24.47 19.15 23.03 
32.39 26.87 20.30 25.43 
33.20 29.66 21.43 27.85 
33.64 32.02 22.64 30.22 
33.90 34.43 23.97 33.02 
34.15 36.85 25.20 35.43 
34.29 39.64 26.44 37.82 
34.25 42.02 27.79 40.25 
34.36 44.42 29.38 43.05 
34.40 46.83 30.94 45.44 
34.23 49.62 32.91 47.81 
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